0

Sarepta’s Eteplirsen Gets Thumbs Down Votes By FDA Advisory Panel

On Monday, an FDA Advisory panel voted down Sarepta Therapeutics (NASDAQ:SRPT) Eteplirsen to treat patients with Duchenne Muscular Dystrophy or DMD. The panel noted concerns with the fact that only 12 patients were recruited in the trial. The truth is that… Continue Reading

0

RXi Pharmaceuticals Patent And Conference Call News Update

On Thursday RXi Pharmaceuticals (NASDAQ:RXII) announced that it had received a patent from the United States Patent and Trademark Office — USPTO — for a patent that covers RXi’s technology sd-rxRNA along with Connective Tissue Growth Factor — CTGF. The patent… Continue Reading

0

Celator Pharmaceuticals Soars 300% On Positive Phase 3 Results In High-Risk AML Patients

In after-hours trading on Monday shares of Celator Pharmaceuticals (NASDAQ:CPXX) soared more than 300% as the company announced positive phase 3 results in a trial with patients with high-risk acute myeloid leukemia. The company’s injectable drug is known as VYXEOS… Continue Reading

0

Celldex Announces Discontinuation Of Phase 3 Trial In Patients With Brain Cancer

On Monday shares of Celldex Therapeutics (NASDAQ:CLDX) fell 53% after the company announced the discontinuation of their phase 3 trial due to insufficient efficacy. The phase 3 trial known as the ACT IV trial recruited up to 745 patients with newly… Continue Reading

0

Shares Of Valeant Tumble Monday On Delayed Earnings And SEC Investigation

On Monday morning Shares of Valeant Pharmaceuticals (NASDAQ:VRX) fell by 7% because of the the company’s delayed financial results which investors have been eagerly awaiting. The delay could likely be linked to the fact that J. Michael Pearson, Valeant’s CEO, has been gone… Continue Reading